Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Aker BioMarine Earnings Release 2020

Feb 16, 2021

3527_rns_2021-02-16_63d71a45-4d0d-4dc6-9625-27d046c6b624.html

Earnings Release

Open in viewer

Opens in your device viewer

Fourth quarter 2020: Promising new product launches and adjusted EBITDA growth of 2.5x YoY

Fourth quarter 2020: Promising new product launches and adjusted EBITDA growth of 2.5x YoY

Fornebu, 16 February 2021 - Aker BioMarine AS (“Aker BioMarine” or “the company”) today announces its results for the fourth quarter 2020.

Fourth quarter highlights:

- Revenues of USD 75.5 million (USD 71.9 million in the corresponding period last year)

- Adjusted EBITDA of USD 21.1 million (USD 8.2 million), with 28% (11%) adjusted EBITDA margin in the quarter

- Net profit of USD 4.2 million (USD -17.8 million)

- Revenue growth of 17% for the full year, USD 289 million (USD 246 million)

- Adjusted EBITDA growth of47% for the full year, USD 78.1 million (USD 53.0 million)

- Continued strong onshore production through the quarter as well as for the full year, delivering record low unit cost

- Harvesting in the quarter was 2,500 MT vs. the expected range of 6,500 - 7,500 MT, lower due to krill appearing later than anticipated in area 48. Harvesting picked up to record levels in the beginning of 2021

- Kori continued to grow the consumer and customer base with new retailers coming in, including Sam’s Club, Rite Aid and Walgreens

- Launch of Lysoveta; a transporter molecule targeting the brain and eye segment. Established partnerships with University of Illinois Chicago for IP and research

- Signed pharma partnership with MD3, for development of five pharma-indications within the eye and brain segment

- Launch of Aion, a circular solution company, delivering fully traceable circular plastic products, also supporting Aker BioMarine’s ambition of full circularity of main waste streams. Plan to spin off in 2021/2022

“It was an eventful year to say the least. Even in the face of Covid-19-related challenges in 2020, our business continued as usual thanks to the relentless efforts and dedication of our global team. We grew our top line by 17%, and we managed to onboard new customers and enter new markets amidst pervasive travel restrictions. I am pleased to see the scalability of Aker BioMarine’s business model coming to life, with a 2020 adjusted EBITDA growth of 47%. Despite the challenges and curveballs thrown at us in 2020, Aker BioMarine delivers strong financial numbers for the year, giving me great optimism for a promising and innovation-filled future,” said Matts Johansen, CEO of Aker BioMarine.

Aker BioMarine invites investors, analysts and other stakeholders to a webcast presentation today at 08:00 am CET. The presentation will be followed by a Q&A session with management. Written questions can be submitted over the Microsoft Live Event.

The presentation will be on webcast only, and in English. To join the videoconference, use the following link:

https://teams.microsoft.com/l/meetup-join/19%3ameeting_ZTIxZTQ4ZmQtZjdkZS00ZDhjLWFiMTktNjE2MmJjNWZjMDcx%40thread.v2/0?context=%7b%22Tid%22%3a%22d02701f9-3b23-4b3f-8fce-29ed54632bf8%22%2c%22Oid%22%3a%2272ea5c6c-fd70-4d89-875b-5e262b94f033%22%2c%22IsBroadcastMeeting%22%3atrue%7d

A replay of the presentation and Q&A session will be made available as soon as possible after the presentation

The quarterly report, presentation material, and webcast will be available at: www.akerbiomarine.com/investor

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

For further information, please contact Martin Stenshall, Investor Relations

Mobile: +47 47 33 83 31

Email: [email protected]

About Aker BioMarine

Aker BioMarine is a biotech innovator and Antarctic krill-harvesting company, dedicated to improving human and planetary health. Listed on Euronext Growth, the company develops krill-based ingredients for nutraceutical (Superba®), aquaculture (QRILL® Aqua), and animal feed applications (QRILL® Pet), including INVI™, a highly concentrated protein isolate, and LYSOVETA™, a targeted transporter of EPA and DHA from krill. Aker BioMarine’s fully transparent value chain stretches from sustainable krill harvesting in pristine Antarctic waters through its Montevideo logistics hub, Houston production plant, and to customers around the world. The company’s strong focus on sustainability inspired the launch of AION by Aker BioMarine, a circularity company dedicated to helping companies to recycle and reuse waste. Read more: www.akerbiomarine.com